Latest news
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 14:18:19 GMTSyndax Pharmaceuticals (SNDX) Stock Climbs On Revenue Strength As Losses Persist - SahmSahm · Thu, 06 Aug 2026 07:00:00 GMTSyndax Pharmaceuticals Q2 Earnings Call Highlights - MarketBeatMarketBeat · Wed, 05 Aug 2026 03:50:06 GMTSyndax Pharmaceuticals (SNDX): Can Revuforj And Niktimvo Power The Next Phase Of Growth? - RTTNewsRTTNews · Mon, 03 Aug 2026 11:36:00 GMTAustralia approves first-in-class Niktimvo for later-line cGVHD - YahooYahoo · Thu, 30 Jul 2026 07:00:00 GMTNiktimvo approval in Australia reinforces momentum for macrophage-targeted cGVHD therapies - The Pharma LetterThe Pharma Letter · Wed, 29 Jul 2026 12:43:46 GMT